(VIANEWS) – The Market ended the session with BERGENBIO (BGBIO.OL) jumping 27.16% to kr0.18 on Thursday while Oslo Børs Benchmark Index_GI slid 0.54% to kr1,252.38.
BERGENBIO’s last close was kr0.14, 98.93% under its 52-week high of kr13.03.
About BERGENBIO
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Earnings Per Share
As for profitability, BERGENBIO has a trailing twelve months EPS of kr-1.65.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -179.58%.
More news about BERGENBIO (BGBIO.OL).
